We are live on ! Find out more
EBS icon

Emergent Biosolutions

172 hedge funds and large institutions have $875M invested in Emergent Biosolutions in 2015 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 76 increasing their positions, 55 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more call options, than puts

Call options by funds: $325K | Put options by funds: $190K

43% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 14

38% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 55

7% more capital invested

Capital invested by funds: $818M → $875M (+$57.1M)

3% more funds holding

Funds holding: 167172 (+5)

0.34% more ownership

Funds ownership: 80.44%80.77% (+0.34%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
172
Holders Change
+5
Holders Change %
+2.99%
% of All Funds
4.58%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
20
Increased
76
Reduced
55
Closed
14
Calls
$325K
Puts
$190K
Net Calls
+$135K
Net Calls Change
+$130K
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of New York Mellon
1
Bank of New York Mellon
New York
$84.2M +$677K +23,618 +0.8%
Vanguard Group
2
Vanguard Group
Pennsylvania
$61.8M +$2.58M +90,099 +4%
BC
3
Broadfin Capital
New York
$52.1M -$7.35M -256,200 -12%
BFA
4
BlackRock Fund Advisors
California
$48.9M +$2.84M +99,056 +6%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$45.9M +$2.72M +94,703 +6%
State Street
6
State Street
Massachusetts
$39.4M +$8M +278,885 +26%
BIT
7
BlackRock Institutional Trust
California
$27.3M +$20.5K +716 +0.1%
Loomis, Sayles & Company
8
Loomis, Sayles & Company
Massachusetts
$22.7M -$1.55M -53,910 -6%
FMA
9
Fiduciary Management Associates
Illinois
$22M -$77.7K -2,710 -0.4%
GT
10
Glenmede Trust
Pennsylvania
$20.7M +$173K +6,046 +0.8%
GC
11
Guggenheim Capital
Illinois
$20.6M -$1.14M -39,786 -5%
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$17.5M +$1.33M +46,301 +8%
Invesco
13
Invesco
Georgia
$17.1M -$625K -21,803 -4%
PI
14
Putnam Investments
Massachusetts
$17.1M +$1.95M +67,858 +13%
Renaissance Technologies
15
Renaissance Technologies
New York
$16.9M +$2.17M +75,700 +15%
UBS AM
16
UBS AM
Illinois
$16.2M +$2.59M +90,167 +19%
Fidelity Investments
17
Fidelity Investments
Massachusetts
$15.7M +$138K +4,800 +0.9%
Charles Schwab
18
Charles Schwab
California
$14.9M +$1.68M +58,521 +13%
Fisher Asset Management
19
Fisher Asset Management
Washington
$14.4M
PRCM
20
Pine River Capital Management
Minnesota
$11.7M
Northern Trust
21
Northern Trust
Illinois
$10.3M +$298K +10,402 +3%
Acadian Asset Management
22
Acadian Asset Management
Massachusetts
$10.1M +$1.41M +49,156 +16%
KCM
23
Kennedy Capital Management
Missouri
$9.61M -$384K -13,394 -4%
ACA
24
Avoro Capital Advisors
New York
$9.51M
NI
25
Numeric Investors
Massachusetts
$8.69M +$8.66M +301,985 New

EBS Hedge Fund Activity: Q1 2015 in Review

172 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q1 2015, worth a combined $875M — up 7% from $818M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new EBS positions and 14 closed out — a net gain of 6 holders — while 76 added to existing stakes and 55 trimmed.

The largest buyer was Numeric Investors, opening a new position worth an estimated $8.66M. The largest seller was Kingdon Capital Management, cutting an estimated $7.51M.

  • 172 institutional investors held Emergent Biosolutions (EBS) as of Q1 2015, up from 167 in Q4 2014.
  • Funds reported $875M of Emergent Biosolutions stock for Q1 2015, up 7% quarter-over-quarter.
  • 20 funds opened new Emergent Biosolutions positions in Q1 2015 and 14 closed out, a net change of +6 holders.
  • The largest Emergent Biosolutions buyer in Q1 2015 was Numeric Investors, an estimated $8.66M added.
  • The largest Emergent Biosolutions seller in Q1 2015 was Kingdon Capital Management, an estimated $7.51M sold.

Based on aggregated 13F filings for Q1 2015.